Achieve Life Sciences, Inc. – NASDAQ:ACHV

Add to watchlist

$2.7

-0.94

-25.82%

Market closed

Open in about 12 hours

-24.64%

month

-24.64%

quarter

-11.44%

year

Market Cap	128.27M
Enterprise value	63.40M

P/E	-1.61
EV/Sales	N/A
EV/EBITDA	-1.72
Price/Sales	N/A
Price/Book	63.04
PEG ratio	-0.06
EPS	-1.29

Revenue	N/A
EBITDA	-24.54M
Income	-27.31M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Profit margin
Jun 2023	0	-8.23M
Sep 2023	0	-7.10M
Dec 2023	0	-5.47M
Mar 2024	0	-6.49M

Achieve Life Sciences Financials Estimate

Q Y

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Analyst Estimates
Mar 2024	0	-6.49M
Sep 2025	0	-4.33M
Oct 2025	0	-5.38M
Dec 2025	0	-4.50M

Analysts Price target
Financials & Ratios estimates

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Debt to assets
Jun 2023	28915000	19.21M	66.46%
Sep 2023	24337000	20.29M	83.41%
Dec 2023	19371000	20.81M	107.48%
Mar 2024	70029000	20.57M	29.38%

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Cash Flow
Jun 2023	-6.67M	0	15.23M
Sep 2023	-5.13M	-15K	0
Dec 2023	-4.36M	-6K	0
Mar 2024	-5.28M	0	56.11M

Achieve Life Sciences alternative data

Achieve Life Sciences
Employees

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Employee count
Aug 2023	20
Sep 2023	20
Oct 2023	20
Nov 2023	20
Dec 2023	20
Jan 2024	20
Feb 2024	20
Mar 2024	20
Apr 2024	20
May 2024	22
Jun 2024	22
Jul 2024	22

Achieve Life Sciences
Hedge Funds Holdings Q1 2023

8.73% -11.90%

of ACHV is owned by hedge funds

19 -8

hedge funds hold ACHV stock

925.15K -1.07M

shares is hold by hedge funds

ACHV hedge funds holdings changes

Achieve Life Sciences
Insider Trading

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Insider trades (number of shares)
Period	Buy	Sel
May 2023	5000	0
Mar 2024	40000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	19 Apr 2024	WAN JERRY officer: Principal Accounting Officer officer: Principal Accounting O..	Common Stock	5,625	N/A	N/A
Option	19 Apr 2024	WAN JERRY officer: Principal Accounting Officer officer: Principal Accounting O..	Performance Restricted Stock Unit (PRSU)	5,625	N/A	N/A
Option	19 Apr 2024	JACOBS CINDY director, officer..	Common Stock	16,250	N/A	N/A
Option	19 Apr 2024	JACOBS CINDY director, officer..	Performance Restricted Stock Unit (PRSU)	16,250	N/A	N/A
Option	19 Apr 2024	STEWART RICHARD ALISTAIR director, officer..	Common Stock	22,500	N/A	N/A
Option	19 Apr 2024	STEWART RICHARD ALISTAIR director, officer..	Performance Restricted Stock Unit (PRSU)	22,500	N/A	N/A
Option	19 Apr 2024	BENCICH JOHN director, officer..	Common Stock	25,000	N/A	N/A
Option	19 Apr 2024	BENCICH JOHN director, officer..	Performance Restricted Stock Unit (PRSU)	25,000	N/A	N/A
Purchase	4 Mar 2024	STEWART RICHARD ALISTAIR director, officer..	Common Stock	10,000	$4.59	$45,850
Purchase	4 Mar 2024	STEWART RICHARD ALISTAIR director, officer..	Common Stock Warrants (right to buy)	10,000	$4.91	$49,060

ACHV insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF Filling date: 2 Jul 2021 Issue date: 28 Oct 2021	2 Jul 2021	28 Oct 2021
Grant	Grant Utility: Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof Filling date: 23 Nov 2020 Issue date: 10 Aug 2021	23 Nov 2020	10 Aug 2021
Grant	Grant Utility: Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof Filling date: 14 Aug 2020 Issue date: 10 Aug 2021	14 Aug 2020	10 Aug 2021
Application	Application COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF Filling date: 23 Nov 2020 Issue date: 18 Mar 2021	23 Nov 2020	18 Mar 2021
Application	Application COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF Filling date: 14 Aug 2020 Issue date: 18 Mar 2021	14 Aug 2020	18 Mar 2021

Achieve Life Sciences
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 9 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 15 Aug 2023	Q2 2023 Earnings Call Transcript

ACHV earnings call transcripts

Achieve Life Sciences
Executives

Insider	Age	Compensation
Dr. Richard A. B. Stewart (1959) Executive Chairman	66	$699,480
Mr. John A. Bencich (1977) Chief Executive Officer & Director	48	$620,520
Dr. Cindy Jacobs M.D., Ph.D. (1958) Pres, Chief Medical Officer & Director	67	$579,810

Achieve Life Sciences
Latest News

Monday, 9 December 2024
08:30	Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer	globenewswire.com
Tuesday, 3 December 2024
08:30	Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA	globenewswire.com
Monday, 25 November 2024
07:54	Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)	globenewswire.com
Thursday, 14 November 2024
08:30	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	globenewswire.com
Saturday, 9 November 2024
07:32	Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 23 October 2024
08:00	Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting	globenewswire.com
Wednesday, 16 October 2024
08:00	Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline	globenewswire.com
Tuesday, 1 October 2024
08:45	Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs	globenewswire.com
Monday, 26 August 2024
16:30	Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors	globenewswire.com
Wednesday, 14 August 2024
04:58	Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 13 August 2024
16:01	Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update	globenewswire.com
Wednesday, 31 July 2024
08:00	Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence	globenewswire.com
Monday, 29 July 2024
08:00	Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank	globenewswire.com
Thursday, 25 July 2024
08:00	Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024	globenewswire.com
Tuesday, 9 July 2024
08:00	Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024	globenewswire.com
Monday, 1 July 2024
13:46	Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement	seekingalpha.com
Friday, 17 May 2024
08:00	Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting	globenewswire.com
Thursday, 9 May 2024
19:58	Achieve Life Sciences, Inc. (ACHV) Q1 2024 Earnings Call Transcript	Seeking Alpha
Thursday, 25 April 2024
08:00	Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024	GlobeNewsWire
Thursday, 4 April 2024
06:30	Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns	Seeking Alpha
Thursday, 28 March 2024
21:03	Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 6 March 2024
08:00	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 12 December 2023
09:10	Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today?	InvestorPlace
08:53	Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatment	Market Watch
Monday, 11 December 2023
16:30	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	GlobeNewsWire
Thursday, 9 November 2023
20:08	Achieve Life Sciences, Inc. (ACHV) Q3 2023 Earnings Call Transcript	Seeking Alpha
Thursday, 26 October 2023
08:00	Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023	GlobeNewsWire
Tuesday, 3 October 2023
08:00	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 1 August 2023
08:00	Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast	GlobeNewsWire
Sunday, 28 May 2023
04:39	Achieve: Exciting Smoking Cessation Drug Approval Could Come Soon	Seeking Alpha

Frequently Asked Questions (FAQ)

What's the price of Achieve Life Sciences stock today?

One share of Achieve Life Sciences stock can currently be purchased for approximately $2.7.
When is Achieve Life Sciences's next earnings date?

Unfortunately, Achieve Life Sciences's (ACHV) next earnings date is currently unknown.
Does Achieve Life Sciences pay dividends?

No, Achieve Life Sciences does not pay dividends.
How much money does Achieve Life Sciences make?

Achieve Life Sciences has a market capitalization of 128.27M.
What is Achieve Life Sciences's stock symbol?

Achieve Life Sciences, Inc. is traded on the NASDAQ under the ticker symbol "ACHV".
What is Achieve Life Sciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Achieve Life Sciences?

Shares of Achieve Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Achieve Life Sciences's key executives?
Achieve Life Sciences's management team includes the following people:
- Dr. Richard A. B. Stewart Executive Chairman(age: 66, pay: $699,480)
- Mr. John A. Bencich Chief Executive Officer & Director(age: 48, pay: $620,520)
- Dr. Cindy Jacobs M.D., Ph.D. Pres, Chief Medical Officer & Director(age: 67, pay: $579,810)
How many employees does Achieve Life Sciences have?

As Jul 2024, Achieve Life Sciences employs 22 workers, which is 10% more then previous quarter.
When Achieve Life Sciences went public?

Achieve Life Sciences, Inc. is publicly traded company for more then 29 years since IPO on 12 Oct 1995.
What is Achieve Life Sciences's official website?

The official website for Achieve Life Sciences is achievelifesciences.com.
Where are Achieve Life Sciences's headquarters?

Achieve Life Sciences is headquartered at 1040 West Georgia Street, Vancouver, BC.
How can i contact Achieve Life Sciences?

Achieve Life Sciences's mailing address is 1040 West Georgia Street, Vancouver, BC and company can be reached via phone at +1 425 686 1500.

Achieve Life Sciences, Inc.

achievelifesciences.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

+1 425 686 1500

1040 West Georgia Street
Vancouver, BC V6E 4H1

CIK: 0000949858
ISIN: US0044685008
CUSIP: 004468203